Physician profile
Seth Levy
NPI 1316980782
$2,295.66
in general payments reported to CMS, 2019-2025
31 companies · $882 in 2025
The $882 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.49 · 2020: $56.33 · 2022: $167 · 2023: $581 · 2024: $569 · 2025: $882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,032.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $411.83 | 2023-2025 | |
| Pfizer INC. | $307.88 | 2019-2025 | |
| Novo Nordisk INC | $235.20 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Axsome Therapeutics, INC. | $121.36 | 2025 | Symbravo |
| Baxter Healthcare | $117.60 | 2022 | |
| Lilly USA, LLC | $115.03 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.11 | 2023 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $90.07 | 2023-2025 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $86.95 | 2023-2025 | Shingrix, Bexsero, Arexvy |
| Merck Sharp & Dohme LLC | $65.85 | 2025 | Capvaxive, Gardasil 9 |
| Becton, Dickinson and Company | $57.81 | 2024-2025 | Bd Max System, Bd Max Instrument, Bd Onclarity |
| Abbott Laboratories | $57.06 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Sanofi Pasteur INC. | $55.30 | 2019-2025 | |
| Ibsa Pharma INC. | $50.31 | 2023-2025 | Licart, Tirosint, Tirosint |
| Janssen Pharmaceuticals, INC | $43.96 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $43.24 | 2023-2024 | Veozah |
| Alk-Abello, INC | $40.17 | 2025 | Neffy, Grastek, Odactra |
| Lundbeck LLC | $38.84 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $36.47 | 2025 | Fanapt |
| Exact Sciences Corporation | $28.84 | 2025 | Cologuard Collection Kit |
| W. L. Gore & Associates, INC. | $28.42 | 2024 | Gore Seamguard Bioabsorbable Staple Line Reinforce |
| Medtronic, INC. | $21.83 | 2024 | |
| Novartis Pharmaceuticals Corporation | $18.88 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.15 | 2023 | Gvoke Hypopen |
| Seqirus USA INC | $17.00 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Kowa Pharmaceuticals America, INC. | $17.00 | 2025 | Zoryve |
| Cumberland Pharmaceuticals, INC. | $15.99 | 2025 | Kristalose |
| Takeda Pharmaceuticals U.S.A., INC. | $15.72 | 2022 | |
| Amgen INC. | $14.25 | 2025 | Evenity |
| Phathom Pharmaceuticals, INC. | $13.95 | 2024 | Voquezna |
| Mallinckrodt Enterprises LLC | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.